Trim 5a was the first member of the tripartite motif (TRIM) family of proteins that was identified to potently restrict human immunodeficiency virus type 1 (HIV-1) replication. The breadth of antiretroviral activity of TRIM family members is an active area of investigation. In this study, we demonstrate that human Trim 37 possesses anti-HIV-1 activity. This antiretroviral activity and the manner in which it was displayed were implicated by (1) decreased viral replication upon Trim 37 transient overexpression in virus-producing cells, (2) correlation of the reduction of viral infectivity with Trim 37 virion incorporation, (3) increased HIV-1 replication during siRNA depletion of Trim 37 expression, and (4) reduction in viral DNA synthesis upon Trim 37 transient overexpression.
INTRODUCTION
Eukaryote cells have evolved specific host cell proteins to limit pathogen attack by providing immunity to infection (Bieniasz, 2004; Goff, 2007; Towers & Goff, 2003) . For retroviruses, a long studied host cell protein is the murine Fv1 protein, which is derived from an endogenous retroviral gag sequence (Best et al., 1996) . Fv1 targets incoming murine leukaemia virus (MLV) capsids and blocks infection after viral DNA synthesis (Jolicoeur & Rassart, 1980) . One family of host cell proteins whose members have been studied in the context of human immunodeficiency virus type 1 (HIV-1) infection is the tripartite motif (Trim) family (Trkola, 2004; Zhang et al., 2011) . All members of the Trim family contain three N-terminal domains -RING, B-box and coiled-coil (Reymond et al., 2001) . Additionally, nearly all members contain one or more variable domains in their C terminus.
Several family-wide screens have been conducted on the antiviral activities of mammalian Trim proteins (Carthagena et al., 2009; Uchil et al., 2008) . These screens have revealed that many members of the Trim family have conserved antiviral activity, especially those family members that contain a SPRY domain as their fourth C-terminal domain (Carthagena et al., 2009; Uchil et al., 2008) , for example, Trim 11, Trim 15 and Trim 22 (Kajaste-Rudnitski et al., 2011; Uchil et al., 2008) . The prototypical SPRY-containing Trim family member that has been shown to have anti-HIV-1 activity is Trim 5a. Recent studies have reported that Trim 5a causes an early block in HIV-1 replication that occurs at or before the initiation of reverse transcription (RT) (Keckesova et al., 2004; Stremlau et al., 2004) . Notably, it was demonstrated that the presence of rhesus Trim 5a leads to a reduction in the amount of late RT (LRT) products, and that Trim 5a associates with retroviral capsids through its SPRY domain (Stremlau et al., 2004; Wu et al., 2006) . Other studies have demonstrated that the Trim 5a B-box domain further stabilizes the SPRY-capsid interaction (Diaz-Griffero et al., 2007 ).
Recently, it was also shown that the linker region between the coiled-coil and SPRY domains determines Trim 5a localization to cytoplasmic bodies, and is essential for Trim 5a antiviral activity (Sastri et al., 2010) . Taken together with previous observations, these findings suggest that multiple domains in Trim 5a are required for and participate in rhesus Trim 5a restriction of HIV-1 replication. Interestingly, Trim 5a capsid recognition abilities have also recently been linked to the newly discovered ability of Trim 5a to catalyse the synthesis of unattached K63 ubiquitin chain, leading to further restriction of HIV-1 infection .
In addition to Trim 5a SPRY-dependent mechanisms of inhibition of HIV-1 infection, some non-SPRY Trim family members have also been implicated to have anti-HIV-1 activity (Uchil et al., 2008) . In the large antiviral Trim IP: 54.70.40.11
On: Fri, 12 Apr 2019 22:15:34 family member screen performed by Uchil and colleagues, Trim 31, which lacks both a coiled-coil and a C-terminal domain, was found to inhibit HIV-1 entry (Uchil et al., 2008) . Furthermore, Trim 32, which contains an NHL C-terminal domain, inhibits HIV-1 long terminal repeat transcription (Fridell et al., 1995) .
In this study, we have found that human Trim 37 -which contains a TRAF domain as its C-terminal domain (Zapata et al., 2001 ) -possesses anti-HIV-1 activity. The anti-HIV-1 activity of Trim 37 was observed by its being able to decrease viral replication upon transient overexpression in virus-producing cells, but not target cells, and this effect could be alleviated via depletion of Trim 37 expression by siRNA. We also found that antiretroviral activity was associated with the recruitment of Trim 37 into virus particles and that the reduction in viral infectivity correlated with a reduction in viral DNA synthesis. Together, these observations provide the first demonstration of the anti-HIV-1 activity of human Trim 37.
RESULTS

Trim 37 expression and inhibition of HIV-1 replication
Previous studies have suggested that Trim 37 is highly conserved and was expressed in all tissues tested (Hämäläinen et al., 2006; Kallijärvi et al., 2006) . To verify these reports, we set out to characterize the expression levels of Trim 37 in a variety of mammalian cell lines in the lab. We examined protein expression levels of Trim 37 in three cell lines (293T, HeLa, HepG2) and in stimulated peripheral blood mononuclear cells (PBMCs) to determine the expression levels of Trim 37 in these cell types. Fig. 1 reveals that Trim 37 was highly expressed in HepG2 cells. Relative to HepG2 cells, Trim 37 protein expression was approximately 11-fold lower in 293T cells, fourfold lower in HeLa cells, and eightfold lower in PBMCs.
Since antiviral activity has been shown for other TRIM family members, we sought to determine whether Trim 37 influenced HIV-1 replication. Results from a yeast twohybrid screen conducted at Myriad Pharmaceuticals indicated that Trim 37 interacted with HIV-1 reverse transcriptase (data not shown), and this further suggested that Trim 37 may influence HIV-1 replication. To test if Trim 37 could influence HIV-1 replication, VSV-G pseudotyped HIV-1 was produced from 293T cells in the presence of varying amounts of Trim 37. The resulting viral supernatants were normalized for p24 levels, and used to infect HeLa target cells; infected cells were identified by green fluorescent protein (GFP) expression. Fig. 2 (a, b) shows that viral infectivity decreases as expression of Trim 37 increases in a dose-dependent manner, though transfection of 10 mg of the Trim 37 expression plasmid into 293T cells did not further decrease viral infectivity beyond that observed by transfection of 5 mg of the Trim 37 expression plasmid ( Fig. 2b ). This suggests that diminution of virus infectivity by Trim 37 expression in 293T may have a saturation limit beyond which no further reduction of virus infectivity can be observed. Our results demonstrate that at the highest level of transfected Trim 37 plasmid, Trim 37 reduced HIV-1 infectivity by approximately 10fold compared with virus produced in its absence as assessed in HeLa cells ( Fig. 2a ). We confirmed by RT-PCR that the increase in Trim 37 mRNA levels correlated with the amount of the Trim 37 plasmid transiently transfected into 293T cells (Fig. 2c ).
The transient expression of Trim 37 in 293T cells was observed to be lower than Trim 37 expression in HepG2 cells ( Fig. 2d ), indicating that the transient expression is within levels observed in other cell types. Infection of HeLa target cells with HIV-1 vector virus produced from HepG2 resulted in elimination of virus infectivity, indicating that saturation of the ability to reduce virus infectivity by higher Trim 37 expression levels observed in 293T cells (i.e. 5 mg to 10 mg, Fig. 2b ) was not apparent in HepG2 cells, as Trim 37 expression levels in these cells correlated with the elimination virus infectivity ( Fig. 2d ). Taken together, these observations suggest cell type differences in the ability of Trim 37 to diminish virus infectivity (e.g. differential ability of Trim 37 to associate with viral protein(s) and assemble into virus particles at increasing Trim 37 expression levels).
We next tested the ability of Trim 37 expression in target cells to block HIV-1 infectivity. To do this, Trim 37 was transiently expressed in HeLa target cells, and 48 h posttransfection cell culture supernatants containing HIV-1 vector virus were used to infect HeLa cells. As indicated in Fig. 2 (e), viral infectivity of HeLa cells transiently transfected with the highest amount (10 mg) of Trim 37 was indistinguishable from that observed in target cells that were mock transfected with empty vector. Parallel experiments performed with 0.5 mg or 5 mg Trim 37 also revealed no differences in HIV-1 infectivity. These observations indicate that the expression of Trim 37 in producer cells, but not in target cells, significantly reduces HIV-1 infectivity. Targeted depletion of endogenous Trim 37 levels increases infectivity
To help exclude the possibility that the antiviral effect of Trim 37 we observed was an artefact of transient Trim 37 expression, we examined the effects of depleting endogenous Trim 37 on infectivity using siRNAs directed against Trim 37 ( Fig. 3 ). Since overexpression of Trim 37 decreases infectivity of HIV-1, we hypothesized that depletion of Trim 37 with siRNA would increase viral infectivity. To examine the ability of Trim 37 siRNA to decrease Trim 37 expression, qPCR was performed 48 h after 293T cells were transiently transfected with Trim 37 siRNA. The results shown in Fig. 3 (a) demonstrate that siRNA treatment decreased Trim 37 mRNA levels by 35 %. This reduction led to a 2.5-fold increase in virus infectivity compared with virus produced in the presence of a control, scrambled siRNA ( Fig. 3b ).
Since we were not able to fully knockdown endogenous Trim 37 gene expression in 293T cells, we further investigated the nature of the Trim 37 gene locus. The Trim 37 gene locus encodes two transcript variants, TV1 and TV2, which lead to the production of the same protein product. We used qPCR to detect transcript variant-specific mRNA expression of Trim 37 in a variety of cell lines (e.g. Bat1, HepG2, 293T, CrFK, MagiU373, Cos1, Vero and HeLa) and detected expression of both transcript variants of Trim 37 in all cell lines (data not shown). These findings are somewhat contrary to previous reports which indicated that only Trim 37 TV1 was expressed in all human and mouse cell types examined, with the exception of testis, which expressed both TV1 and TV2 (Kallijärvi et al., 2006) . The 39 untranslated region (39UTR) of Trim 37 TV2 overlaps with the 39UTR of a neighbouring gene, PPM1E, in humans and other species. PPM1E can be amplified from these cell lines, suggesting that mRNA hybridization between Trim 37 and PPM1E could occur. The physiological relevance of the Trim 37 and PPM1E overlap has not been determined (Kallijärvi et al., 2006) . The inability to knockdown PPM1E gene expression using shRNA has recently been reported (Voss et al., 2011) , providing further indication of the difficulties in using interfering technologies to reduce gene expression in this region.
Investigation of Trim 37 incorporation into HIV-1 particles
To determine whether Trim 37 was packaged into HIV-1 particles, we analysed Trim 37 virion incorporation into an HIV-1 vector, pHIG. Seventy-two hours post-transfection of 293T cells with Trim 37 and pHIG, cell culture supernatants were collected and virus particles were purified by ultracentrifugation through a 20 % sucrose cushion. The particles were lysed, subjected to SDS-PAGE, and analysed for Trim 37 incorporation. As shown in Fig. 4(a) , the 130 kDa Trim 37 protein was readily detected when Trim 37 was co-transfected into cells. The amount of Trim 37 co-transfected did not significantly affect the amount of HIV-1 Gag incorporated into virus particles or the efficiency of virus particle production (Fig. 4a, bottom  panel) . This indicates that Trim 37 was incorporated into virus particles in a dose-dependent manner (Fig. 4a, b ).
We next tested if Trim 37 could be incorporated into HIV-1-like particles produced from an HIV-1 Gag-only expression construct. To do this, the Gag-only expression construct was co-transfected with varying amounts of Trim 37 into 293T cells. Particles released into cell culture supernatants were analysed by immuoblot ( Fig. 4c ). Gag incorporation into particles was not affected by Trim 37 co-expression ( Fig. 4c ). Trim 37, however, was not detected in the virus particles, although both Trim 37 and Gag were detected in cell lysates. These data suggest that the viral protein determinants required for Trim 37 incorporation into particles involve an HIV-1 protein other than Gag.
Analysis of viral DNA synthesis in infected cells
To determine if Trim 37 influences the levels of viral DNA synthesis, quantitative real-time PCR was used to detect RT intermediates from infected target cells. HeLa cells were infected with HIV-1 p24 capsid-equivalent amounts of virus. RT products were detected from 4 to 24 h postinfection and the absolute quantities synthesized were determined by a standard curve. Fig. 5(a) 2-to 18-fold reduction in the synthesis of minus-strand strong stop (SS) DNA when using virus produced in the presence of varying levels of Trim 37. The initial amount of minus-strand DNA detected at 4 h did not increase over time, suggesting some viral DNA synthesis was initiated, albeit at low levels. The synthesis of late RT products was, like the early RT products, at low levels (Fig. 5b) . These observations suggest that the presence of Trim 37 is associated with a severe inhibition of viral DNA synthesis, but that a low level of viral DNA synthesis occurred prior to full establishment of the Trim 37 antiviral effect.
DISCUSSION
This study has identified the human Trim 37 protein as possessing anti-HIV-1 activity. The anti-HIV-1 activity of human Trim 37 was implicated by (1) decreased viral replication upon Trim 37 transient overexpression in virus-producing cells, (2) correlation of the reduction of viral infectivity with Trim 37 virion incorporation, (3) increased HIV-1 replication during siRNA depletion of Trim 37 expression, and (4) reduction in viral DNA synthesis upon Trim 37 transient overexpression.
One potential mechanism to explain the anti-HIV-1 activity of Trim 37 is that viral DNA synthesis is perturbed by interaction between Trim 37 and RT. The lack of Trim 37 incorporation with Gag-only virus-like particles provides an indication that a viral protein(s) other than Gag was required for Trim 37 virion incorporation. It is formally possible that Trim 37 causes premature uncoating. Rhesus Trim 5a is thought to cause a reduction in viral DNA products. The SPRY-domain-containing rhesus Trim 5a is rapidly degraded after exposure to HIV-1 capsids, but this degradation can be blocked by proteasomal inhibition (Rold & Aiken, 2008) . Several groups have confirmed that proteasomal inhibition does not result in a relief of the block of HIV-1 infectivity, although it does result in an increase in viral DNA products (Perez-Caballero et al., 2005; Stremlau et al., 2006; Wu et al., 2006) .
Our evidence of the anti-HIV-1 activity of Trim 37 was not predicted from a family-wide Trim screen for anti-HIV activity (Uchil et al., 2008) . In these studies, it was found that human Trim 37 did not inhibit HIV or MLV entry when target cells were transfected with Trim 37 plasmid, then challenged with MLV or HIV-1 virus pseudotyped with ALV-A 30 h later. This experimental design parallels our experiments with target cells (see Fig. 2e ), and corroborates our findings that Trim 37 does not exert a target cell effect. This observation provides one line of evidence that the HIV-1 capsid protects RT, and why target cell Trim 37 does not affect viral replication. However, it is 293T cells were transfected with pHIG and pCMV-G in the presence of the indicated amounts of pTrim37. Forty-eight hours post-transfection, cell culture supernatants were harvested and virus particles were pelleted through a sucrose cushion. The viral particle pellets were resuspended, lysed and subjected to SDS-PAGE. Immunoblot analysis was done using antibodies directed against Trim 37 and p24 Gag. (b) Relative amounts of Trim 37 incorporated into HIV-1 particles. Error bars indicate SD. (c) 293T cells were cotransfected with human codon optimized gag and the expression plasmid for Trim 37. Forty-eight hours post-transfection, cell culture supernatants and cells were harvested. The virus-like particle pellets or cells were resuspended, lysed and subjected to SDS-PAGE. Immunoblot analysis was done using antibodies directed against Gag and Trim 37.
possible that no target cell effect was observed due to the lack of stable Trim 37 expression in target cells.
Like rhesus Trim 5a, Trim 37 exerts its antiviral activity in the early phase of HIV-1 replication. However, our data indicate that Trim 37 has an antiviral mechanism that is distinct from that of rhesus Trim 5a. Trim 37 was incorporated into HIV-1 particles and its expression severely diminished viral DNA synthesis. While Trim 5a interacts with the HIV-1 capsid through its SPRY domain, Trim 37, however, lacks a SPRY domain. For its variable C-terminal domain, Trim 37 contains a TRAF, also referred to as a MATH motif (Lehesjoki et al., 2001) . While siRNA depletion of Trim 37 resulted in only a modest reduction (,50 %), virus infectivity increased by 2.5-fold. This could be indicative of a critical threshold of Trim 37 expression needed in order to see an effect on HIV-1 infectivity.
The evolutionary conservation of the Trim family suggests that the antiviral properties of human Trim 37 could apply to other retroviruses. It is therefore plausible that Trim 37 from other species could be more potent in the inhibition of HIV-1 replication. Comparative studies should be useful in determining the molecular mechanism for the perturbation of viral DNA synthesis and the anti-HIV-1 mechanism of Trim 37.
METHODS
Cell culture and plasmid constructs. The HEK293T, HepG2 and HeLa cells were maintained in Dulbecco's modified Eagle's medium (GIBCO) supplemented with penicillin and streptomycin and 10 % fetal clone III serum (Hyclone) at 37 uC in 5 % CO 2 . The single-cycle HIV-1 vector, pHIG, contains an expression cassette consisting of the mouse heat-stable antigen CD24 (HSA) gene, an internal ribosomal entry site and the enhanced green fluorescence protein (EGFP) gene, which was cloned into the nef gene. This vector does not express the envelope protein due to a 59 frame shift mutation in the envelope gene. A Trim 37 expression plasmid previously described (Avela et al., 2000) was generously provided by Dr Anna-Elina Lehesjoki (University of Helsinki, Finland). A vector that encodes the vesicular stomatitis virus glycoprotein (pCMV-VSV-G) was used to pseudotype the HIV-1 vector for production of virus. An HIV-1 Gag-only expression vector, pHIVGag, was constructed by codon optimization of the HIV-1 Gag gene sequence.
Single-round replication assays. Vector virus stocks for singleround HIV-1 infectivity assays were produced by DNA transfection of 293T cells or HepG2 cells. Cells were grown on poly-L-lysine-coated 10 cm dishes, and were transfected using the calcium phosphate DNA precipitation method. Each 10 cm dish was co-transfected with 10 mg viral vector (pHIG) and 1 mg p-CMV-VSV-G. To assess effects of Trim 37 in 293T cells, the vector encoding Trim 37 was co-transfected at 0.5 mg, 5 mg or 10 mg. Additionally, the levels of plasmid DNA were normalized for each transfection by adding the appropriate level of an empty bacterial vector, such that each transfection contained 21 mg DNA in total. Twenty-four hours after transfection, the medium was changed, and 20 mM HEPES was added to the culture medium. Cell culture supernatants from either 293T or HepG2 cells were harvested 48 h post-transfection, filtered through a 0.2 mm filter, and normalized for p24 Gag prior to infection of target cells (Dapp et al., 2009) . Two days post-infection, virus infectivity was assessed by measuring EGFP fluorescence using flow cytometry.
Trim 37 RNA depletion by siRNA. Downregulation of Trim 37 expression by siRNA was done by transfecting cells with siRNA against Trim 37 (Invitrogen) using Lipofectamine (Invitrogen) according to the manufacturer's instructions.
Virion incorporation and co-immunoprecipitation assays.
Lysates were prepared from either cells or viral pellets by resuspending the pellets in RIPA buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 % NP-40, 0.5 % deoxycholate (DOC), 0.1 % SDS and 5 mM EDTA pH 8.0). Viruses were harvested by filtration (0.2 mm) of then probed with either a rabbit anti-Trim 37 antibody (Novus Biologicals or Bethyl Laboratories), or a rabbit anti-p24 antibody (Advanced Biotechnologies). Membranes were then incubated with goat anti-rabbit IgG-HRP secondary antibody conjugates, and the proteins were visualized by chemiluminescence using the Bio-Rad Gel Doc (Bio-Rad).
To assess Trim 37 virion incorporation, Trim 37 was detected with a rabbit anti-Trim 37-specific antibody (Novus Biologicals). The levels of p24 Gag were used to normalize for equal loading of viral particle lysates as previously described (Dapp et al., 2009) . Briefly, ELISA plates (96-well) were incubated overnight with a 1 : 1000 rabbit p24 antiserum (AIDS Reagent Program, catalogue no. 4250). The ELISA plates were then washed with PBS-0.5 % Tween 20 (PBST) and blocked for 1 h with 3 % milk in PBST. The samples and standards were prepared by adding a 1 : 1 volume of PBS-0.1 % Empigen (Sigma-Aldrich) and incubating at 56 uC for 30 min. The samples were then added to the plate and incubated at 37 uC for 1 h. Wells were washed with PBST and then incubated with mouse anti-p24 in PBST-1 % milk at 22 uC for 1 h. Incubation was then done with a horseradish peroxidase conjugated anti-mouse secondary antibody in PBST-1 % milk for 30 min, and the wells were washed with PBST and PBS before the addition of the tetramethylbenzidine substrate. The reactions were stopped by the addition of 1 M sulfuric acid, and the absorbance was determined at 450 nm.
For experiments requiring co-immunoprecipitation, viral lysates were incubated with either a monoclonal antibody directed against reverse transcriptase (no. 11338, NIH AIDS Research Program) or a rabbit anti-Trim 37 antibody.
Real-time reverse transcriptase PCR. Total RNA was extracted from 293T or HeLa cells using the RNeasy kit from Qiagen and cDNA was prepared using SuperScript III Reverse Transcriptase (Invitrogen). Quantitative PCR was performed in triplicate with 1 ml cDNA on an ABI Prism 7400 cycler, using Applied Biosystems SYBR Green master mix. The Trim 37 primer pair was designed to amplify all transcript variants of human Trim 37 (NM_015294) cDNA: 59-GTCGCGTCTCATGGAACT (forward) and 59-CTACAAGACCG-CAACTGGTG (reverse). The primer pairs designed to amplify Trim 37 TV1 only were TGGAAACTGTTGGAAGGTGGCACA (forward) and GCATTCAGCAAGACATCAGACACGG (reverse). The primer pairs designed to amplify Trim 37 TV2 only were TGTGACACTGA-GAATGAGGAGCAGG (forward) and TGGCCCCAACTATAGTG-CCGG (reverse). The primer pairs designed to amplify PPM1E were TGGAGGTTGCGTAGTCTGGT (forward) and CGGTGTCATAG-AAGCCATCAC (reverse). Plasmid DNA encoding Trim 37 was used as a standard.
Real-time PCR analysis of viral DNA synthesis. Infected cells were incubated with DNase-treated virus for 4, 6, 12 or 24 h. DNA was prepared from the cells by resuspending cell pellets in lysis buffer (0.1 M Tris pH 8.5, 5 mM EDTA pH 8.0, 200 mM NaCl, 0.2 % SDS and 2 mg ml 21 proteinase K) and incubating at 55 uC overnight. qPCR analysis of reverse transcriptase products was performed using 1 ml lysate. Samples were then analysed using primer pairs that had been previously established (Carr et al., 2007) for amplification of viral SS or LRT DNA products. The following primer pairs were used: 59-CTAACTAGGGAACCCACTGC and 59-CTGCTAGAGATTTTC-CACAC (SS DNA), and 59-TGTGTGCCCGTCTGTTGTGT, 59-G-AGTCCTGCGTCGAGAGAGC (LRT DNA). PCRs were carried out with a denaturation step of 10 min at 95 uC followed by 40 cycles of 15 s at 95 uC, 15 s at annealing temperature of 55 uC and 30 s amplification at 72 uC. Quantification of DNA products was determined with reference to HIV-1 vector plasmid, which was used as a standard.
